fenofibrate has been researched along with bicyclol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Dong, H; Fong, WF; Ko, KM; Pan, SY; Wang, H; Xiang, CJ; Yu, ZL; Zhao, XY | 1 |
2 other study(ies) available for fenofibrate and bicyclol
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice.
Topics: Analysis of Variance; Animals; Bile Acids and Salts; Biphenyl Compounds; Cholesterol; Cholesterol, Dietary; Cyclooctanes; Dose-Response Relationship, Drug; Fenofibrate; Hypercholesterolemia; Hypolipidemic Agents; Intubation, Gastrointestinal; Lipids; Liver; Male; Mice; Mice, Inbred ICR; Tablets; Time Factors; Triglycerides | 2007 |